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Abstract 
Background: Diabetes and impaired glucose tolerance (IGT) are major risk factors for atherosclerosis including coro-
nary artery disease (CAD). The present study’s aim was to investigate the importance of glucose tolerance for long-
term clinical outcome in patients with acute coronary syndrome (ACS).
Methods: A total 1062 consecutive patients, 781 men and 281 women, aged 32–80 years, admitted to the coronary 
care unit at Danderyd University Hospital, Stockholm, for ACS from 2006 to 2008 were included. At discharge, the 
patients were categorized according to an oral glucose tolerance test (OGTT) as having normal glucose tolerance 
(NGT), n = 295 (28 %); impaired fasting glucose (IFG) and IGT, n = 299 (28 %); diabetes discovered by OGTT, n = 156 
(15 %); or known diabetes at admission, n = 312 (29 %). Mortality and reinfarction rates were studied during a mean 
follow-up time of 4.0 (±0.8) years. Clinical outcome data were obtained from the Swedish Coronary Angiography and 
Angioplasty Registry and the Swedish National Registry.
Results: There was significantly higher (p < 0.001) mortality within, 30 days, 1 and 3 years in patients with known 
diabetes as compared to the other groups. During the follow-up, 86 patients (28 %) with known diabetes had reinfarc-
tion as compared to 36 patients (12 %) with NGT and 79 patients (17 %) with dysglycaemia (IFG, IGT and diabetes) 
discovered by OGTT.
Conclusion: A majority (72 % in this study) of patients admitted for ACS have disturbed glucose metabolism, includ-
ing diabetes, with high prevalence of previously undiagnosed dysglycaemia. Both patients with known diabetes and 
dysglycaemia discovered by OGTT show a high risk for poor clinical prognosis.
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Background
There is a global increase in the prevalence of type 2 
diabetes mellitus (T2DM) and impaired glucose toler-
ance (IGT), which are major risk factors for atheroscle-
rosis including acute coronary syndrome (ACS) caused 
by coronary artery disease (CAD) [1, 2]. T2DM and IGT 
have been shown to occur among as many as two-thirds 
of patients with ACS and previously unknown diabe-
tes [3, 4]. A long-term follow-up of these patients has 
demonstrated that these newly detected glucose distur-
bances also affect future prognosis [4].
The Euro Heart Survey shows that a majority of patients 
diagnosed with CAD including ACS have abnormal glu-
cose regulation [5], and two earlier studies that included 
previously healthy individuals showed that IGT leads to 
an increased risk of cardiovascular disease (CVD) and 
death [6, 7]. There are several factors contributing to 
why patients with T2DM and IGT are particularly prone 
to develop ACS. Among these are vascular endothe-
lial dysfunction, disturbed platelet function, decreased 
fibrinolytic capacity, high levels of advanced glycation 
end products (AGEs), dyslipidemia, hypertension and 
reduced insulin sensitivity [8–12].
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T2DM develops slowly through stages of early impair-
ments of glucose metabolism. A majority of subjects who 
develop T2DM demonstrate IGT approximately 5  years 
prior to diagnosis [13]. With regard to ACS, the research 
to date has tended to focus on diabetes rather than IGT. 
Thus, the impact of IGT on ACS, and cardiovascular 
morbidity and mortality in general, is yet to be revealed. 
A large study of patients with CAD showed that diabe-
tes, whether it is previously known or newly detected, 
is an independent risk factor for mortality and myocar-
dial infarction during a 1-year follow-up period [14]. 
Impaired glucose regulation, including IGT and impaired 
fasting glucose (IFG), was not an independent predic-
tor of adverse outcomes in these patients [14]. However, 
over a longer period of time, glucose levels far below 
the threshold for diabetes have been shown to markedly 
increase the risk of cardiovascular events [15].
The primary aim of the present study was to investigate 
the importance of dysglycaemia detected by an oral glu-
cose tolerance test (OGTT) for long-term mortality and 
cardiovascular events in patients with ACS.
Methods
Patients
Included in the study were 1062 consecutive patients, 281 
women and 781 men, aged 32–80 years, admitted to the 
coronary care unit at Danderyd Hospital for myocardial 
infarction or unstable angina between January 19, 2006 
and December 29, 2008. All patients, except patients with 
known type 1 or type 2 diabetes, underwent a stand-
ardised 75-g OGTT according to WHO criteria [16] at 
4–5  days after admission. According to the American 
Diabetes Association document from 1997 [17], the cri-
teria for IFG were a fasting plasma glucose level of ≥6.1 
to <7.0 mmol/l and a 2-h plasma glucose level at OGTT 
<7.8 mmol/l; and for IGT, a fasting plasma glucose level 
<6.1 mmol/l and a 2-h plasma glucose level at OGTT of 
≥7.8 to <11.1  mmol/l. T2DM was defined as having a 
fasting plasma glucose value ≥7.0 mmol/l, and/or a 2-h 
plasma glucose value at OGTT ≥11.1 mmol/l.
Myocardial infarction and unstable angina pectoris 
were defined according to the criteria recommended by 
the Joint European Society of Cardiology and the Ameri-
can College of Cardiology Committee [18].
Protocol
Data were collected in two steps:
1. Baseline data and OGTT results were collected at the 
time of admission from 2006 to 2008.
2. Retrospective review of the Swedish Web system for 
Enhancement and Development of Evidence-based 
Care in Heart Disease Evaluated According to Rec-
ommended Therapies Registry (SWEDEHEART) and 
the Swedish Coronary Angiography and Angioplasty 
Registry (SCAAR) was performed in 2012.
Statistical analysis
Data are presented as mean ± standard deviation (SD) or 
in percentage when categorical values. The Kruskal–Wal-
lis test followed by Mann–Whitney’s U test (Table 1) or 
Chi square test (Tables 1, 2, 3, 4) was performed to ana-
lyse differences in continuous variables between groups. 
Data shows absolute risks. Statistical significance was set 
at p  <  0.05. Data processing was performed using IBM 
SPSS, version 22.
Ethical considerations
All participants received written and oral information 
regarding the study and gave their written informed con-
sent. The study protocol was approved by the local Ethics 
Committee at Karolinska Institutet.
Results
Glucose tolerance
Table 1 shows the distribution of women and men with 
ACS in all glucose tolerance groups. In total, 76 (27.0 %) 
women and 219 (28.0 %) men had NGT, and the corre-
sponding figures for IFG/IGT were 77 (27.4  %) women 
and 222 (28.4 %) men; for patients with diabetes discov-
ered by OGTT, numbers were 40 (14.2  %) women and 
116 (14.9  %) men. Finally, 88 (31.3  %) women and 224 
(28.7  %) men had known diabetes at admission to the 
hospital. Among patients with diabetes, 31 (9.9  %) had 
type 1 diabetes (data not shown).
Basic characteristics and ACS diagnosis
Table  1 shows that individuals with disturbances of 
glucose tolerance were older than those with NGT 
(p < 0.001), and that patients with known diabetes were 
older than individuals with IFG/IGT as well as patients 
with diabetes discovered by OGTT (p  <  0.01). There 
was a significant increase in BMI in individuals with 
disturbances of glucose tolerance compared to subjects 
with NGT (p < 0.01), and patients with known diabetes 
had significantly higher BMI than individuals with IFG/
IGT (p  <  0.01). Furthermore, diastolic blood pressure 
was lower in patients with known diabetes compared to 
individuals with IFG/IGT (p  <  0.001), while there were 
no significant differences in systolic blood pressure lev-
els between the four groups. At the time of admission, 
patients with known diabetes had higher serum cre-
atinine levels (p < 0.001) as well as higher prevalence of 
previous acute myocardial infarction (AMI), coronary 
artery bypass graft (CABG) and percutaneous coronary 
intervention (PCI) (p < 0.01) compared to the three other 
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groups. Furthermore, the prevalence of smoking was 
less (p  <  0.05) among patients with diabetes discovered 
by OGTT as compared to the other groups. Table 1 also 
shows that the prevalence of previous hypertension was 
higher in patients with known diabetes compared to the 
other three groups (p < 0.001), and higher in individuals 
with IFG/IGT compared to NGT and patients with dia-
betes discovered by OGTT (p < 0.001).
Among individuals with NGT, 14.6  % were diagnosed 
with unstable angina pectoris and 85.4  % AMI, and 
among individuals with IFG/IGT, 11.7 % were diagnosed 
with unstable angina pectoris and 88.3 % AMI. The cor-
responding numbers among patients with diabetes dis-
covered by OGTT were 15.4 and 84.6  %, respectively. 
Among patients with known diabetes at admission to 
the hospital, 16.0 % were diagnosed with unstable angina 
pectoris and 84.0 % had AMI.
In‑hospital treatment and events
Table 2 shows that patients with known diabetes less fre-
quently underwent coronary angiography and PCI, and 
were more often treated with drug-eluting stents (DES) 
instead of bare metal stents (BMS). In total, 928 of 1062 
patients underwent coronary angiography; 612 of 928 
patients underwent PCI, and 537 of 612 patients were 
treated with stents, of which, 415 of 537 got DES, and 122 
of 537 got BMS. Furthermore, the evaluation of the left 
ventricular ejection fraction (LVEF) was performed less 
in patients with known diabetes as compared to the other 
three groups. The prevalence of reduced ejection fraction 
was significantly higher in patients with known diabetes 
as compared to the other groups (p < 0.001).
Medical treatment at hospital discharge is shown in 
Table  3. Aspirin, clopidogrel and statins were used less 
frequently in patients with known diabetes compared to 
individuals with NGT, IFG/IGT and patients with dia-
betes discovered by OGTT. Calcium antagonists, angi-
otensin II receptor blockers and diuretics were more 
frequently used among patients with known diabetes 
compared to the other three groups. Finally, there was no 
significant difference in the use of beta-blockers, while 
ACE inhibitors were less frequently used among individ-
uals with NGT. Among patients with diabetes discovered 
by OGTT, 7.3 % were started on oral antidiabetic medi-
cation at the time of discharge.
Mortality and reinfarction
Table 4 shows that there was significantly higher mortal-
ity within 30 days, 1 and 3 years in the group with known 
diabetes at admission compared to individuals with NGT 
and dysglycaemia (IFG, IGT and diabetes) discovered by 
OGTT (p < 0.001). The 3-year mortality among patients 
with type 1 diabetes was approximately 60  % (data not 
shown). Figure 1 shows the cumulative mortality within 
3  years in relation to the various glucose tolerance 
groups, which include NGT, dysglycaemia discovered by 
Table 1 Basic characteristics in 1062 patients at time of admission for acute coronary syndrome
Values are means (SD). Presented values are unadjusted
CABG coronary artery bypass graft, PCI percutaneous coronary intervention
vs NGT, a p < 0.05, b p < 0.01, c p < 0.001; vs IFG/IGT, d p < 0.05, e p < 0.01, f p < 0.001; vs Diabetes OGTT, g p < 0.05, h p < 0.01, i p < 0.001; vs known diabetes, j p < 0.05, 
k p < 0.01, l p < 0.001
m Significance testing after adjustment for age, BMI, and sex, for the variables systolic blood pressure and diastolic blood pressure
Ω Chi square test
A Patients with diabetes discovered by OGTT
B Patients with known diabetes at admission
NGT IFG/IGT DiabetesA DiabetesB P
No. 295 299 156 312
Female/male (n) 76/219 77/222 40/116 88/224 NS
Age (years) 61.4 (9.81)e,h,l 63.9 (10.40)b,l 64.3 (8.77)b,k 66.9 (8.99)c,f,h <0.001
BMI (kg/m2) 25.9 (3.96)e,i,l 27.1 (3.92)b,k 27.8 (3.81)c 28.5 (5.00)c,e <0.001
Systolic blood pressurem (mm/Hg) 143.9 (27.84) 148.7 (28.87) 147.6 (29.69) 144.8 (29.77) NS
Diastolic blood pressurem (mm/Hg) 82.9 (14.26) 85.4 (15.49)l 83.6 (13.90) 80.2 (15.34)f <0.001
S-Creatinine (µmol/L) 84.0 (19.95)l 86.7 (33.40)l 81.9 (17.44)l 111.6 (89.31)c,f,i <0.001
Previous (%)
 Acute myocardial infarction 14.7l 19.6l 12.9l 52.7c,f,h <0.001Ω
 Hypertension 16.7f,l 25.7c,i,l 16.9f,l 40.7c,f,i <0.001Ω
 CABG 14.6l 17.7l 14.6l 53.1c,f,h <0.001Ω
 PCI 21.1l 17.9l 15.4l 45.5c,f,h <0.001Ω
 Smokers 26.9g 26.7g 15.8a,d,j 30.6g <0.05Ω
Page 4 of 8Kuhl et al. Cardiovasc Diabetol  (2015) 14:120 
OGTT, and patients with known diabetes. The cumula-
tive mortality within 3  years was significantly higher in 
patients with known diabetes compared to the other two 
groups.
During a follow-up time of 4.0 (±0.8) years, 86 patients 
(28 %) with known diabetes had reinfarction as compared 
to 36 patients (12 %) with NGT and 79 patients (17 %) 
with dysglycaemia discovered by OGTT.
Discussion
The results of the present study show that a majority of 
patients with ACS had dysglycaemia, in other words, 
Table 2 In-hospital treatment and events in 1062 patients with acute coronary syndrome
Parenthesis show number of individuals
PCI percutaneous coronary intervention, BMS bare metal stents, DES drug-eluting stents, CABG coronary artery bypass graft, LVEF left ventricular ejection fraction
vs NGT, a p < 0.05, b p < 0.01, c p < 0.001; vs IFG/IGT, d p < 0.05, e p < 0.01, f p < 0.001; vs Diabetes OGTT, g p < 0.05, h p < 0.01, i p < 0.001; vs known diabetes, j p < 0.05, 
k p < 0.01, l p < 0.001
A Patients with diabetes discovered by OGTT
B Patients with known diabetes at admission
NGT IFG/IGT DiabetesA DiabetesB P
No. 295 299 156 312
Female/male (n) 76/219 77/222 40/116 88/224 NS
Coronary angiography  % 92.5 (273)l 94.0 (281)l 92.3 (144)l 73.7 (230)c,f,i <0.001
 Coronary angio-graphy in 928 patients
  PCI  % (of 928) 70.7 (193)l 66.5 (187)l 69.4 (100)l 57.4 (132)c,f,i <0.05
  PCI in 612 patients
   Stent  % (of 612) 87.0 (168) 87.7 (164) 87.0 (87) 89.4 (118) NS
   Stent in 537 patients
    BMS % 81.5 (137)l 82.9 l (136) 81.6 (71)l 60.2 (71)c,f,i <0.001
    DES % 18.5 (31)l 17.1l (28) 18.4 (16)l 39.8 (47)c,f,i <0.001
CABG  % 13.9 (41) 16.7 (50) 16.7 (26) 17.9 (56) NS
LVEF evaluation  % 83.4 (246)l 83.3 (249)l 87.2 (136)l 76.0 (237)c,f,i <0.001
Normal LVEF (>50 %) 74.4 (183)l 72.3 (180)l 67.6 (92)l 50.6 (120)c,f,i <0.001
Reduced LVEF (<50 %) 25.6 (63)l 27.7 (69)l 32.4 (44)l 49.4 (117)c,f,i <0.001
Table 3 Medical treatment at hospital discharge in 1062 patients with acute coronary syndrome
vs NGT, a p < 0.05, b p < 0.01, c p < 0.001; vs IFG/IGT, d p < 0.05, e p < 0.01, f p < 0.001; vs Diabetes OGTT, g p < 0.05, h p < 0.01, i p < 0.001; vs known diabetes, j p < 0.05, 
k p < 0.01, l p < 0.001
A Patients with diabetes discovered by OGTT
B Patients with known diabetes at admission
NGT IFG/IGT DiabetesA DiabetesB P
No. 295 299 156 312
Female/male (n) 76/219 77/222 40/116 88/224 NS
Treatment at discharge (%)
 Aspirin 97.8l 97.5l 96.7l 89.4c,f,i <0.001
 Clopidogrel 80.6l 81.1l 80.0l 66.7c,f,i <0.001
 Beta-blockers 94.7l 96.1l 97.3l 95.0c,f,i NS
 Calcium antagonists 9.2l 14.6l 9.3l 24.6c,f,i <0.001
 ACE inhibitors 51.2f,i,l 62.6c 70.7c 63.8c <0.001
 Angiotensin II receptor blockers 7.8f,i,l 12.5c,l 12.0c,l 21.9c,f,i <0.001
 Diuretics 8.9f,i,l 16.8l 16.7l 42.5c,f,i <0.001
 Statins 94.7l 92.9l 95.3l 88.0c,f,i <0.01
 Oral antidiabetic medication 0i,l 0i,l 7.3c,f,l 56.1c,f,i <0.001
 Insulin 0l 0l 0l 52.7c,f,i <0.001
 Oral antidiabetic medication and Insulin 0l 0l 0l 26.3c,f,i <0.001
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known diabetes or disturbed glucose metabolism discov-
ered by OGTT.
Patients with known diabetes had significantly higher 
short- and long-term mortality as compared to both 
patients with NGT and those with dysglycaemia discov-
ered by OGTT; however, the latter group showed a non-
significant trend towards higher long-term mortality as 
compared to the patients with NGT.
The baseline characteristics between patients with 
NGT and abnormal OGTT were not significantly differ-
ent, while patients with known diabetes had significantly 
higher co-morbidity as seen with, for example, previ-
ous myocardial infarction, higher serum creatinine and 
BMI, which, in addition to higher age, can at least partly 
explain the poor outcome in these patients. Furthermore, 
the prevalence of systolic left ventricular (LV) dysfunc-
tion measured by echocardiography was significantly 
higher in patients with known diabetes. Echocardio-
graphic parameters such as ejection fraction and myocar-
dial strain reflecting LV systolic function, are associated 
with clinical outcome in patients with myocardial infarc-
tion [19, 20], and LV function is one the strongest predic-
tors of outcome following PCI [21].
We found a high incidence of previously undiagnosed 
diabetes and/or IFG/IGT among patients with ACS. 
Notably, a substantial proportion of patients who died 
or had myocardial infarction during the follow-up were 
characterized as dysglycaemic, in other words, as hav-
ing known diabetes at admission or disturbed glucose 
metabolism diagnosed by OGTT. Interestingly, the 
results indicate worsened prognosis, i.e. higher mortal-
ity and reinfarction for every stage that dysglycaemia 
progresses, that is, a trend towards higher mortality and 
reinfarction in patients with positive OGTT as compared 
to NGT, and significantly higher mortality and reinfarc-
tion in patients with known diabetes as compared to 
NGT. T2DM is preceded by disturbed glucose metabo-
lism which at least at early stages may pass undiag-
nosed and untreated for several years. Disturbed glucose 
metabolism, also at early stages, seems to have a progres-
sive adverse effect on the cardiovascular system reflected 
as poor clinical outcome, most significantly in patients 
with manifest diabetes. Early diagnosis and treatment of 
impaired glucose metabolism may slow down or even 
reverse the adverse effects on the cardiovascular system, 
while irreversible damages occur when impaired glucose 
metabolism progresses untreated to manifest diabetes.
Previous retrospective studies have investigated the 
prevalence of dysglycaemia and its influence on clinical 
outcome in patients with CAD [22–30]. However, the 
accuracy of the results of some of these studies is wor-
thy of discussion either due to the methods that were 
used to diagnose diabetes, which included fasting blood 
glucose and HbA1c levels, or inclusion of patients with 
Table 4 Patient mortality and reinfarction (281 women and 781 men)
vs NGT a p < 0.001; vs IFG/IGT and diabetes OGTT b p < 0.001; vs known diabetes, c p < 0.001
A Patients with diabetes discovered by OGTT
B Patients with known diabetes at admission
NGT IFG/IGT and diabetesA DiabetesB P
No. 295 455 312
Death within 30 days, n (%) 0c 1 (0.2)c 15 (4.8)a,b <0.001
Death within 1 year, n (%) 0c 9 (2.0)c 39 (12.5)a,b <0.001
Death within 3 years, n (%) 9 (3.1)c 23 (5.1)c 77 (24.7)a,b <0.001
Reinfarction, n (%) 36 (12.2)c 79 (17.4)c 86 (27.6)a,b <0.001
Fig. 1 Kaplan–Meier curves showing cumulative mortality within 
3 years. Kaplan–Meier curves showing cumulative death within 
3 years. Blue line represents patients with NGT, green line patients with 
IFG + IGT and diabetes discovered by OGTT, and beige line patients 
with known diabetes at admission
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different diagnosis of CAD, such as, for example, stable 
vs ACS, associated with different short- and long-term 
prognosis. In the present study, we performed OGTT to 
investigate the glycaemic status of all patients with pre-
viously unknown DM. The European Diabetes Society 
and European guidelines on cardiology recommend the 
performance of OGTT in patients with CVD, especially 
in those with ACS. In patients with ACS, an abnormal 
OGTT seems to be a better prognostic marker than fast-
ing blood glucose [31–34] or HbA1c alone [34].
Although the importance of hyperglycaemia as a pre-
dictor of survival in patients with ACS is well established, 
the association between dysglycaemia and mortality 
might differ across the spectrum of CAD [35]. In the 
present study, we included only patients with ACS, in 
other words, those with unstable angina and myocardial 
infarction.
In our study a substantial number of patients with 
known diabetes were treated conservatively; that is, sig-
nificantly fewer patients underwent coronary angiog-
raphy and PCI. The reason why a less invasive approach 
was chosen in the treatment of patients with known dia-
betes in this study is unclear. One reason could be that 
patients with known diabetes had already undergone 
coronary angiography during previous admissions since 
more patients in this group had previous MI, and perhaps 
based on previous examinations and/or decisions, a more 
conservative approach was chosen when the patient was 
readmitted with a new event. Another possible explana-
tion concerns the risks of kidney dysfunction caused by 
the contrast given during coronary angiography and PCI, 
in other words, contrast-induced nephropathy (CIN), 
since the renal function was already significantly dete-
riorated in these patients as compared to patients in the 
two other groups. Higher age and existence of significant 
co-morbidities may also have played a role in choosing a 
more conservative approach. A non-invasive treatment 
strategy may have influenced the long-term prognosis 
in patients with known diabetes, as it has been demon-
strated that an invasive strategy in the management of 
patients with ACS reduces long-term cardiovascular 
mortality and morbidity [36].
Although kidney dysfunction influences the likelihood 
of choosing an invasive treatment strategy in patients 
with ACS [37], previous studies have shown that an early 
invasive therapy is associated with better clinical out-
come in patients with mild to moderate kidney dysfunc-
tion [38]. However, kidney function remains a significant 
prognostic marker of outcome following PCI [21]. The 
interrelationship between kidney dysfunction and treat-
ment strategy as, for example, with invasive vs non-inva-
sive approaches, in patients with diabetes and ACS has 
not been fully investigated.
Of note, a majority of patients with known diabetes 
who underwent PCI were treated with bare metal stents 
(BMS), and less than 20  % of the patients with dysgly-
caemia detected by OGTT received drug-eluting stents 
(DES), since they were treated as non-diabetic patients 
at the time of PCI. As demonstrated in our study, a sig-
nificant number of patients with positive OGTT before 
discharge from the hospital were actually treated as non-
diabetic patients at the time of admission and, more 
importantly, during coronary angiography and PCI, 
which may have influenced the treatment strategies such 
as stent choice, thus possibly contributing to worse clini-
cal outcome as seen in these patients [21]. These find-
ings highlight the necessity of investigating glycaemic 
status early in patients with ACS as, for example, before 
coronary angiography, since it has influence on therapeu-
tic strategies such as PCI vs CABG, choice of stent, and 
more. However, since this study was performed, the use 
of DES has increased tremendously in our department 
as well as all over Sweden, and currently the majority of 
patients, with or without diabetes, receive DES.
Due to the lack of initial symptoms, the diabetes diag-
nosis may be delayed for several years, even after enter-
ing a diabetic state [39]. The duration and severity of the 
disease are of great importance for cardiovascular risk 
as well as other diabetic complications. Both improved 
metabolic and blood pressure control has been shown to 
decrease morbidity and mortality in patients with CAD. 
Glycated haemoglobin (HbA1c) is commonly used as a 
measure of metabolic control. There is a strong relation-
ship between HbA1c levels and mortality in patients with 
CAD, which is independent of other risk factors [40, 41]. 
In patients with ACS, high HbA1c levels are associated 
with worse short-term outcome [22, 42], and elevated 
levels of HbA1c are associated with the progression and 
difficulty of CAD [43]. However, improved glycaemic 
control was not associated with a decreased incidence 
of macrovascular complications or mortality [44]. In the 
present study, there are no available data of HbA1c at the 
time of admission and/or during hospital stay, and no 
data regarding glycaemic and blood pressure control dur-
ing follow-up.
Today there is no consensus among cardiologists how 
to treat patients with T2DM or IGT, and which glucose-
lowering therapy is optimal after a coronary event. One 
large clinical trial found that treatment with insulin in 
patients with myocardial infarction was associated with 
an enhanced risk of recurrent nonfatal myocardial infarc-
tion or stroke, while treatment with metformin was more 
beneficial [45, 46].
Another study found that insulin treatment with or with-
out oral glucose-lowering therapy was associated with 
higher long-term mortality in patients with DM undergoing 
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coronary angiography [47]. T2DM patients are often treated 
with high insulin doses leading to weight gain and high 
blood pressure and, despite intensified insulin therapy, the 
treatment goals, which also include improved metabolic 
control and tight blood pressure control, are not reached.
A limitation of our study is when interpreting the 
results one should take into consideration that this is a 
retrospective single-center study analysing register data 
lacking information regarding long-term glycaemic con-
trol and incidence of CIN during the follow-up period 
which are important predictors of outcome in patients 
with ACS. Furthermore, the register data from SWEDE-
HEART and SCAAR does not provide information 
regarding changes of medical therapy including antidia-
betic treatment during the follow-up period.
Conclusions
The results of the present study show that undiagnosed 
dysglycaemia is common in patients with ACS. Both 
known diabetes and newly detected dysglycaemia showed 
increased risk for poor long-term clinical outcome, while 
short-term mortality was greater among patients with 
known diabetes. Routine OGTT in patients with ACS is 
useful for detecting undiagnosed dysglycaemia; however, 
new therapeutic approaches are needed to improve long-
term prognosis in these patients.
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